Search

Your search keyword '"Kardos G"' showing total 410 results
Start Over Author "Kardos G"
410 results on '"Kardos G"'

1. Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis

Author

Prépost E, Tóth Z, Perlin DS, Gesztelyi R, Kardos G, Kovács R, Nagy F, Forgács L, and Majoros L

Subjects
humanized caspofungin doses, intermittent dosing regimen of echinocandins, Candida albicans complex, fungal tissue burden, echinocandin resistance, Infectious and parasitic diseases, RC109-216
Abstract

Eszter Prépost,1 Zoltán Tóth,1 David S Perlin,2 Rudolf Gesztelyi,3 Gábor Kardos,1 Renátó Kovács1,4 Fruzsina Nagy,1 Lajos Forgács,1 László Majoros11Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 2Public Health Research Institute, New Jersey Medical School-Rutgers, Newark, NJ, USA; 3Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 4Faculty of Pharmacy, University of Debrecen, Debrecen, HungaryBackground: Echinocandins are the first-line therapy for treatment of invasive Candida infections, but the mortality rate remains high, calling for novel strategies. Giving single larger echinocandin doses infrequently is an alternative regimen. Our aim was to test this novel approach in a neutropenic murine model.Materials and methods: We compared the in vivo efficacy of single 10 and 40 mg/kg of caspofungin (2.5× and 10× the normal humanized dose) to that of the same cumulative doses of daily 2 and 8 mg/kg doses for 5 days against 2 each of wild-type C. albicans and C. dubliniensis as well as echinocandin resistant C. albicans. As a comparator, we tested daily 1 mg/kg amphotericin B.Results: In lethality experiments, all caspofungin and amphotericin B regimens improved survival against wild-type C. albicans and C. dubliniensis clinical isolates (P

Published
2019

11. High co-prevalence of genogroup 1 TT virus and human papillomavirus is associated with poor clinical outcome of laryngeal carcinoma

Author

Szladek, G., Juhasz, A., Kardos, G., Szoke, K., Major, T., Sziklai, I., Tar, I., Marton, I., Konya, J., Gergely, L., and Szarka, K.

Subjects
TT virus infections -- Research, TT virus infections -- Complications and side effects, Papillomavirus infections -- Research, Papillomavirus infections -- Complications and side effects, Laryngeal cancer -- Research, Laryngeal cancer -- Causes of, Health
Published
2005

29. Expression of Cell Differentiation Antigens as a Prognostic Factor in Acute Leukemia

Author

Hołowiecki, J., Lutz, D., Callea, V., Brugiatelli, M., Krzemień, S., Stella-Hołowiecka, B., Neri, A., Ihle, R., Schranz, V., Graf, F., Kelenyi, G., Jagoda, K., Zintl, F., Reves, T., Kardos, G., Barceanu, S., Neth, Rolf, editor, Gallo, Robert C., editor, Greaves, Melvyn F., editor, Gaedicke, Gerhard, editor, Gohla, Sven, editor, Mannweiler, Klaus, editor, and Ritter, Jörg, editor

Published
1989
Full Text
View/download PDF

39. Iatrogene gevolgen van kanker op de kinderleeftijd

Author

Postma, A., Behrendt, H., Groot-Loonen, J.J., Hakvoort-Cammel, F.G.A.J., Kardos, G., Weel-Sipman, M.H. van, and Pediatrics

Subjects
Late effects after treatment of children with malignancies, Onderzoek naar late gevolgen na behandeling van kinderen met maligniteiten
Abstract

Item does not contain fulltext 5 p.

Published
1999

41. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.

Author

Kardos, G., Zwaan, C.M., Kaspers, G.J.L., Graaf, S.S.N. de, Bont, E.S. de, Postma, A., Bökkerink, J.P.M., Weening, R.S., Does-van den Berg, A. van der, Wering, E.R. van, Korbijn, C., Hahlen, K., Kardos, G., Zwaan, C.M., Kaspers, G.J.L., Graaf, S.S.N. de, Bont, E.S. de, Postma, A., Bökkerink, J.P.M., Weening, R.S., Does-van den Berg, A. van der, Wering, E.R. van, Korbijn, C., and Hahlen, K.

Abstract

Contains fulltext : 49234.pdf (publisher's version ) (Closed access), This report describes the long-term follow-up data of three consecutive Dutch Childhood Oncology Group acute myeloid leukemia (AML) protocols. A total of 303 children were diagnosed with AML, of whom 209 were eligible for this report. The first study was the AML-82 protocol. Results were inferior (5-year probability of overall survival (pOS) 31%) to other available regimes. Study AML-87 was based on the BFM-87 protocol, with prophylactic cranial irradiation in high-risk patients only, and without maintenance therapy. This led to a higher cumulative incidence of relapse than that reported by the Berlin-Frankfurt-Munster (BFM), but survival was similar (5-year pOS 47%), suggesting successful retrieval at relapse. The subsequent study AML-92/94 consisted of a modified BFM-93 protocol, that is, without maintenance therapy and prophylactic cranial irradiation. However, all patients were to be transplanted (auto- or allogeneic), although compliance was poor. Antileukemic efficacy was offset by an increase in the cumulative incidence of nonrelapse mortality, especially in remission patients, and survival did not improve (5-year pOS 44%). Our results demonstrate that outcome in childhood AML is still unsatisfactory, and that further intensification of therapy carries the risk of enhanced toxicity. Our patients are currently included in the MRC AML studies, based on the results of their AML 10 trial.

Published
2005

44. From farm to fork follow-up of thermotolerant campylobacters throughout the broiler production chain and in human cases in a Hungarian county during a ten-months period

Author

Damjanova, I., primary, Jakab, M., additional, Farkas, T., additional, Mészáros, J., additional, Galántai, Zs., additional, Turcsányi, I., additional, Bistyák, A., additional, Juhász, Á., additional, Pászti, J., additional, Kiss, I., additional, and Kardos, G., additional

Published
2011
Full Text
View/download PDF

46. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: A preliminary report

Author

Gertjan Kaspers, Kardos, G., Pieters, R., Zantwijk, C. H., Klumper, E., Hählen, K., Waal, F. C., Wering, E. R., Veerman, A. J. P., Pediatric surgery, AII - Cancer immunology, CCA - Cancer biology and immunology, and CCA - Cancer Treatment and quality of life

Subjects
hemic and lymphatic diseases
Abstract

The better prognosis of acute lymphoblastic leukemia (ALL) than of acute non-lymphoblastic leukemia (ANLL) in children, and the often observed better prognosis of myeloid-antigen (MyAg) negative ALL than of MyAg-positive ALL, may be related to differences in cellular drug resistance. We therefore compared the resistance to 12 drugs of 125 ALL and 28 ANLL samples with the MTT assay. ALL samples were median > 75-fold more sensitive to the glucocorticoids prednisolone and dexamethasone (p < 0.00001), and 2-fold more sensitive to vincristine (p = 0.05) than ANLL samples. Differences for the other drugs were not significant. MyAg-negative ALL samples were more sensitive to glucocorticoids than MyAg-positive ALL-samples (p ≤ 0.04). Prednisolone, and dexamethasone if tested, had a stimulatory effect on leukemic cell survival in 36% of ANLL, but in only 2% of ALL samples (p < 0.0001). Vincristine, and vindesine if tested, had a similar effect in 11% of ANLL, and in 4% of ALL samples (p = 0.11). We conclude that the more favorable response of ALL against ANLL to combination chemotherapy in children may be explained by the higher antileukemic activity of glucocorticoids and of vincristine in ALL, while none of the drugs was more active in ANLL. Similarly, the better prognosis of MyAg-negative ALL than of MyAg-positive ALL may be explained by a relative sensitivity to glucocorticoids. Glucocorticoids and vinca-alkaloids induced leukemia cell proliferation in part of the samples, most frequently in ANLL. The findings may be useful in the design of new chemotherapeutic regimens for ALL and ANLL.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results